GO
Loading...

Pharmaceuticals

More

  • *FDA lists 10 violations at Taiwan plant. July 29- Impax Laboratories Inc said the U.S. Food and Drug Administration raised concerns about the company's factory in Taiwan, casting in doubt the future of its Parkinson's drug, rytary.

  • Merck & Pfizer beat the Street     Tuesday, 29 Jul 2014 | 10:14 AM ET

    CNBC's Meg Tirrell reports both Merck and Pfizer beat earnings expectations amid patent expirations.

  • July 29- Impax Laboratories Inc said the U.S. Food and Drug Administration issued certain observations regarding violations in the company's manufacturing plant in Taiwan. Shares of Impax, which makes generics and specialty drugs to treat central nervous system disorders, fell about 17 percent to $23.15 premarket on Tuesday.

  • July 29- Merck& Co Inc reported better-than-expected quarterly results on Tuesday, with sales of consumer products and medicines for arthritis and HIV helping to offset the impact of generic competition on other drug sales. Merck, the No. 2 U.S. drugmaker, earned $2.03 billion, or 68 cents per share, in the second quarter.

  • Big pharma tax attack     Tuesday, 29 Jul 2014 | 8:04 AM ET

    Fundamentally, U.S.-based companies are at a disadvantage because of our tax code, says Barbara Ryan, FTI Consulting, sharing her thoughts on tax inversion among the big pharma space.

  • Big pharma by the numbers     Tuesday, 29 Jul 2014 | 8:02 AM ET

    What we are seeing is innovation is not dead, says Barbara Ryan, FTI Consulting, discussing Pfizer and Merck's second quarter results and big Pharma drug trends.

  • Pfizer's 2Q profit sinks 79 pct but tops forecasts Tuesday, 29 Jul 2014 | 7:37 AM ET

    Pfizer's second-quarter earnings plunged 79 percent from last year, when the world's second-largest drugmaker booked a $10 billion- plus gain from a business spinoff.

  • Pfizer to renew AstraZeneca bid?     Tuesday, 29 Jul 2014 | 5:50 AM ET

    Ranjith Gopinathan, programme manager, life sciences and healthcare practice at Frost & Sullivan, discusses pharmaceutical groups Merck and Pfizer ahead of their quarterly results.

  • China to put Glaxo investigators on trial Aug. 8 Tuesday, 29 Jul 2014 | 4:24 AM ET

    BEIJING— A Shanghai court says American and British investigators who worked for drug maker GlaxoSmithKline will stand trial Aug. 8 on charges of illegally obtaining information on Chinese citizens. 1 Intermediate People's Court said Tuesday that Yingzeng Yu and her husband Peter Humphrey will have a "public trial."

  • Americans fighting Ebola contract deadly virus Monday, 28 Jul 2014 | 8:10 AM ET
    Staff of the Christian charity Samaritan's Purse putting on protective gear in the ELWA hospital in the Liberian capital Monrovia, July 24, 2014.

    Americans Dr. Kent Brantly and aid worker Nancy Writebol contracted Ebola while working to fight the disease in Liberia. NBC News reports.

  • Pfizer's need for deal looms with earnings report Monday, 28 Jul 2014 | 7:12 AM ET

    Pfizer's vulnerability to cheap generics and its weak roster of experimental medicines will be on display Tuesday, when the company reports earnings.

  • NEW YORK, July 28- Pfizer Inc's vulnerability to cheaper generics and its weak roster of experimental medicines will be on display Tuesday when the company reports quarterly earnings, reviving interest in its pursuit of AstraZeneca Plc or other deals to fortify its pipeline.

  • Virus drugmaker fights pediatricians' new advice Monday, 28 Jul 2014 | 12:01 AM ET

    CHICAGO— A costly drug given mostly to premature babies is at the center of a clash between the manufacturer and the nation's leading pediatrician's group, which recommends scaling back use of the medicine.

  • July 25- AbbVie Inc, which last week announced plans to buy Dublin- based drugmaker Shire Plc for $55 billion, reported stronger-than-expected quarterly results on surging sales of its Humira treatment for rheumatoid arthritis. Excluding special items, AbbVie earned 82 cents per share.

  • FDA reviewing what could be first biosimilar drug Thursday, 24 Jul 2014 | 3:41 PM ET

    Nearly five years after Congress passed a law enabling future approval of biosimilars, for the first time the FDA has accepted an application to sell a similar, but not identical, version of a biologic drug.

  • Reversing a lower court ruling, the 2nd U.S. Circuit Court of Appeals in New York said the FDA was empowered to reject two citizen challenges to its policy, which discourages but does not ban the use of penicillin and some tetracyclines in feed for chickens, cows and pigs, even if they are not sick.

  • Deadly 'superbug' is spreading in US hospitals Thursday, 24 Jul 2014 | 2:03 PM ET

    CRE, one of the worst of the superbugs, is spreading in some hospitals, and there's worry that cases are under-reported.

  • EXCLUSIVE-Allegations of GSK corruption spread to Syria Thursday, 24 Jul 2014 | 1:19 PM ET

    LONDON, July 24- GlaxoSmithKline faces new allegations of corruption, this time in Syria, where the drugmaker and its distributor have been accused of paying bribes to secure business, according to a whistleblower's email reviewed by Reuters.

  • Reversing a lower court ruling, the 2nd U.S. Circuit Court of Appeals in New York said the FDA was empowered to reject two citizen challenges to its policy, which discourages but does not ban the use of penicillin and some tetracyclines in feed for chickens, cows and pigs, even if they are not sick.

  • Man tested for Ebola in Africa's 'megacity' Lagos Thursday, 24 Jul 2014 | 11:57 AM ET

    A Liberian man is being tested for the deadly Ebola virus in Nigeria's commercial capital of Lagos, a megacity of 21 million people.